{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:54:42Z","timestamp":1781848482545,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Various guidelines recommend offering germline genetic testing to all patients diagnosed with epithelial ovarian cancer, as it helps guide treatment decisions, identify cancer risks in other organs, and empowers patients to notify families for timely screening and risk-reducing surgery. Our study aimed to explore the awareness and uptake rate of germline genetic testing among Chinese women with epithelial ovarian cancer, and to analyze the determinants influencing their decision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross sectional study was conducted at Obstetrics and Gynecology Hospital of Fudan University between November 2023 to September 2024.\u00a0A questionnaire was used to assess patients\u2019 awareness of germline genetic testing. Disease-related data were extracted from electronic medical records. Binary logistic regression analysis was performed to identify factors associated with uptake of germline genetic testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the total 154 patients included, 100 underwent germline genetic testing, with an uptake rate of 64.94%. Among included patients, 62.99% demonstrated low awareness of germline genetic testing and 37.01% exhibited a high level of awareness. Logistic regression analysis showed that higher monthly per-capita household income (OR = 3.30, 95 % CI 1.24-8.75, P = 0.017), a family history of\n                      <jats:italic>BRCA<\/jats:italic>\n                      -related cancers (OR\u00a0=\u00a06.30, 95% CI 1.16-34.12, P\u00a0=\u00a00.033), and high awareness of germline genetic testing (OR = 8.81, 95 % CI 2.58-30.12, P = 0.001) were associated with a significantly increased likelihood of undergoing testing. Additionally, 19.6% of the tested patients carried a pathogenic variant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among Chinese patients with epithelial ovarian cancer, awareness of germline genetic testing is generally low, with critical deficiencies in knowledge that directly inform clinical decision-making and familial risk management. Nearly two-thirds of patients diagnosed with epithelial ovarian cancer had undergone germline genetic testing. Socioeconomic status, family history of associated cancer, and patients\u2019 awareness of genetic testing are the principal determinants of germline genetic testing utilization in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1876816","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:15Z","timestamp":1781848035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Awareness, uptake, and determinants of germline genetic testing in Chinese epithelial ovarian cancer patients: a cross-sectional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xia","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]},{"name":"School of Nursing Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yuan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Han","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Nursing Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"You","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Jiao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174344","article-title":"Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-0692-y","article-title":"Mainstreaming germline BRCA1\/2 testing in non-mucinous epithelial ovarian cancer in the North West of England","volume":"28","author":"Flaum","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.024","article-title":"BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls","volume":"151","author":"Li","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00295","article-title":"Germline and somatic BRCA1\/2 mutations in 172 chinese women with epithelial ovarian cancer","volume":"10","author":"You","year":"2020","journal-title":"Front Oncol"},{"key":"B5","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): genetic\/familial high-risk assessment: breast, ovarian, and pancreatic (Version 3.2023)","year":"2023"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002112","article-title":"British Gynaecological Cancer Society\/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1\/2 variants in ovarian cancer in the United Kingdom","volume":"31","author":"Sundar","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-Related cancer: US preventive services task force recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.05.011","article-title":"Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis","volume":"162","author":"Lin","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a Population-Based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_350292","article-title":"Genetic testing for all: Overcoming disparities in ovarian cancer genetic testing","volume":"42","author":"Frey","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1002360","article-title":"Overview on population screening for carriers with germline BRCA mutation in China","volume":"12","author":"Lei","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004958","article-title":"Temporal patterns and adoption of germline and somatic BRCA testing in ovarian cancer","volume":"140","author":"Huepenbecker","year":"2022","journal-title":"Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-005190","article-title":"Delivery of hereditary cancer genetics services to patients newly diagnosed with ovarian and endometrial cancers at three gynecologic oncology clinics in the USA, Brazil, and Mexico","volume":"34","author":"Bednar","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100029","article-title":"BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway","volume":"35","author":"Birgisdottir","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001261","article-title":"BRCA testing in women with high-grade serous ovarian cancer: Gynecologic oncologist-initiated testing compared with genetics referral","volume":"30","author":"Piedimonte","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18052312","article-title":"The knowledge and attitude of patients diagnosed with epithelial ovarian cancer towards genetic testing","volume":"18","author":"Shin","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152541","article-title":"Barriers and breakthroughs in precision oncology: A national registry study of BRCA testing and PARP inhibitor uptake in women from the national Gynae-Oncology registry (NGOR)","volume":"17","author":"Naidoo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10689-025-00467-7","article-title":"Evaluation of BRCA1\/2 testing rates in epithelial ovarian cancer patients: Lessons learned from real-world clinical data","volume":"24","author":"Lanjouw","year":"2025","journal-title":"Fam Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001168","article-title":"Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer","volume":"30","author":"Alimena","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29120735","article-title":"Referral, genetic counselling, and BRCA testing in the manitoba High-Grade serous ovarian cancer population, 2004-2019","volume":"29","author":"Winchar","year":"2022","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000384","article-title":"The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)","volume":"29","author":"Enomoto","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000630","article-title":"Mainstreamed genetic testing in ovarian cancer: Patient experience of the testing process","volume":"30","author":"McLeavy","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad328","article-title":"Development of an electronic decision aid tool to facilitate mainstream genetic testing in ovarian cancer patients","volume":"29","author":"Shannon","year":"2024","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2196\/31263","article-title":"Understanding the information needs of patients with ovarian cancer regarding genetic testing to inform intervention design: Interview study","volume":"8","author":"Zhang","year":"2022","journal-title":"JMIR Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines? Insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Cancer Network JNCCN"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-Year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pecinn.2023.100138","article-title":"Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis","volume":"2","author":"Ahsan","year":"2023","journal-title":"PEC Innovation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000895","article-title":"Uptake of cascade genetic testing for hereditary breast and ovarian cancer: A systematic review and Meta-Analysis","volume":"67","author":"Ahsan","year":"2024","journal-title":"Clin Obstet Gynecol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:16Z","timestamp":1781848036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1876816"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876816","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1876816"}}